Date: April 20, 2023
Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEST)
Multiplexed antibody-based imaging enables the characterization of cellular interactions, spatial relationships, and histological patterns in tissues. These techniques require considerable resources and domain expertise for implementation, limiting their widespread adoption. To overcome these challenges, we developed Iterative Bleaching Extends multi-pleXity (IBEX), an open-source method that can be completed at relatively low cost in 2-5 days by biologists with basic laboratory skills. In addition to cost-effective techniques such as IBEX, community initiatives are needed to extend the reach of multiplexed tissue imaging. The IBEX Imaging Community is an international group of scientists committed to sharing knowledge related to multiplexed imaging in a transparent and collaborative manner. Organ Mapping Antibody Panels (OMAPs) are community-validated resources that save time and money, increase reproducibility, and support the construction of a Human Reference Atlas. This webinar will provide guidelines for the successful application of IBEX to a wide range of scientific questions using diverse imaging platforms. A significant amount of time will be devoted to the following topics: optimal tissue processing, working with fixed frozen and FFPE specimens, identifying appropriate reagents, and constructing organ atlases. Team science initiatives will be highlighted to encourage attendees to join and accelerate discovery together.
Learning Objectives
- Apply key tips and tricks to help with adopting multiplexed antibody-based imaging methods in your laboratory
- Discuss community resources for multiplexed imaging
- Explain how tissue atlases can be mapped using IBEX
Webinars will be available for unlimited on-demand viewing after live event.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.